Lantern Pharma’s LP-284 Shows Complete Response in Refractory B-Cell Cancer, Validating AI-Driven Drug Development
Lantern Pharma Inc. (NASDAQ: LTRN) presented compelling clinical data for its AI-developed oncology drug candidate LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress, highlighting a complete metabolic response in a patient with aggressive diffuse large B-cell lymphoma (DLBCL) who had failed four prior therapies, including CAR-T and bispecific antibody treatments. The patient achieved remission after just two 28-day cycles, validating LP-284’s synthetic lethal mechanism that targets DNA repair deficiencies through transcription-coupled nucleotide excision repair (TC-NER). Unlike current therapies, LP-284 remains effective regardless of TP53 mutation status or surface antigen expression and can overcome resistance to BTK and proteasome inhibitors. The therapy addresses a critical $3–4 billion market gap in relapsed or refractory B-cell cancers, particularly for post-CAR-T and post-bispecific patients. Developed using Lantern’s RADR® AI platform, LP-284 has shown favorable safety with mainly mild side effects and demonstrated synergy with rituximab in preclinical models. Lantern is now pursuing strategic partnerships to advance combination trials and expand clinical development, supported by multiple FDA Orphan Drug Designations, strong IP protection through 2039, and interest from biopharma collaborators. The results mark a major milestone in validating Lantern’s AI-driven approach to oncology drug development and highlight LP-284’s potential as both a standalone and combination therapy for patients with advanced B-cell cancers.
Lantern Pharma’s LP-284 Shows Complete Response in Refractory B-Cell Cancer, Validating AI-Driven Drug Development